Rational design and synthesis of sulfonamide-substituted coumarinyl-imidazolone hybrids against multidrug-resistant microbial strains: computational and biological evaluation studies
Future Medicinal Chemistry · 18.10.2026 · 18 (20) · 2877-2892
DOI: 10.1080/17568919.2026.2736295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Medicinal Chemistry, online erschienen am 24.09.2026. Verfasst von Preetesh Kumar Panda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India. Hauptthemen laut MEDLINE: Coumarins, Drug Design, Sulfonamides, Imidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
AIM: The longstanding use of sulfonamides has contributed to the emergence of multidrug-resistant (MDR) pathogens, posing a major challenge to antimicrobial therapy worldwide. In response, a series of sulfonamide-linked coumarinyl-imidazolone derivatives (6a-t) were rationally designed and synthesized to identify potential antimicrobial candidates. MATERIALS AND METHODS: Structures were confirmed by spectroscopic techniques. In silico studies, including molecular docking, molecular dynamics (MD) simulations, and ADMET analysis, correlated with the observed biological activity. RESULTS: Compounds 6a (-11.97 kcal/mol) and 6m (-9.91 kcal/mol) demonstrated excellent binding toward C. albicans sterol 14α-demethylase (CYP51) and PBP2a of methicillin-resistant S. aureus (MRSA), respectively, while MD simulations support stable complexes. In vitro findings identified compounds 6a, 6m, and 6n as potent leads, exhibiting significant antimicrobial activity with minimum inhibitory concentration (MIC) values ranging from 15 to 500 µg/mL and antioxidant activity with DPPH IC50 values of 6.05 ± 0.57, 7.57 ± 0.36, and 6.35 ± 0.51 μM, respectively. Frontier Molecular Orbital (FMO) analysis further substantiated the reactivity and stability of the lead candidates, with compound 6n displaying the lowest energy gap (2.66 eV), indicating enhanced reactivity. CONCLUSIONS: Compounds 6a, 6m, and 6n exhibited potent antimicrobial and antioxidant activities, highlighting their promise as multifunctional antimicrobial scaffolds against MDR pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicinal Chemistry Research Laboratory, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India.
- Department of Skin & VD, Institute of Medical Sciences and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University, Bhubaneswar, India.
- Central Research Laboratory, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, India.
Zitieren
APA
Panda, P. K., Paidesetty, S. K., Sahoo, A., Ghose, A., & Bishoyi, A. K. (2026). Rational design and synthesis of sulfonamide-substituted coumarinyl-imidazolone hybrids against multidrug-resistant microbial strains: computational and biological evaluation studies. Future Medicinal Chemistry, 18(20), 2877-2892. https://doi.org/10.1080/17568919.2026.2736295
Vancouver
Panda PK, Paidesetty SK, Sahoo A, Ghose A, Bishoyi AK. Rational design and synthesis of sulfonamide-substituted coumarinyl-imidazolone hybrids against multidrug-resistant microbial strains: computational and biological evaluation studies. Future Medicinal Chemistry. 2026;18(20):2877-2892. doi:10.1080/17568919.2026.2736295
BibTeX
@article{Panda2026,
author = {Panda, Preetesh Kumar and Paidesetty, Sudhir Kumar and Sahoo, Alaka and Ghose, Aruna and Bishoyi, Ajit Kumar},
title = {Rational design and synthesis of sulfonamide-substituted coumarinyl-imidazolone hybrids against multidrug-resistant microbial strains: computational and biological evaluation studies},
journal = {Future Medicinal Chemistry},
year = {2026},
volume = {18},
number = {20},
pages = {2877--2892},
doi = {10.1080/17568919.2026.2736295}
}
EUVIMED